LONDON (Alliance News) - 4D Pharma PLC said Friday it has entered into a EUR4.8 million four-year collaboration project with the APC Microbiome Institute at University College Cork to focus on researching the potential applications of live biotherapeutics in relation to Autism Spectrum Disorders and associated central nervous system disorders.
The company said the programme will focus on strains it has identified as potentially therapeutically relevant through its MicroRx platform.
"There is a high unmet medical need for safe and efficacious therapies which treat the core symptoms of Autism Spectrum Disorders," said Chief Executive Officer Duncan Peyton in a statement.
"Using our proprietary MicroRx platform this work has led to rapid identification of candidates that are now undergoing a development programme prior to human trials. We believe the collaboration with the APC will further the understanding and treatment of diseases such as Autism Spectrum Disorders with live biotherapeutics and reinforce the emergence of this new therapeutic class," Peyton added.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
